What this means
This is a trial that has not reported results yet. It will test whether a sugar called trehalose, given for 14 days, changes blood vessel function in people with diabetes.
Plain-English summary written by an AI model from the registry listing.
- Status
- Recruiting
- Who can join
- Ages 18–80
- Where
- 1 site, including Wisconsin
The science
- Registered title
- Role of Autophagy in Type 2 Diabetes Microvascular Dysfunction
- Trial ID
- NCT05593549 ↗
- Phase
- EARLY PHASE 1
- Study type
- interventional
- Conditions
- Type 2 Diabetes, Healthy Aging
- What is tested
- Trehalose, Placebo
- Sponsor
- Medical College of Wisconsin
- Ages
- 18 Years to 80 Years
- Dates
- First posted Oct 25, 2022 · updated Oct 30, 2025
Registry summary
The goal of this clinical trial is to examine the role of autophagy on microvascular function in adults with Type 2 Diabetes. The main question it aims to answer are:
- Does presence of Type 2 Diabetes reduce autophagy and impair microvascular function?
- Does exposure to high glucose impair autophagy and subsequently microvascular function?
Participants will undergo 2 study days. The primary outcome will be in vivo microvascular function testing. Following the first study day participants will undergo either supplementation with trehalose, an autophagy activator, or placebo for 14 days. The second study day will test in vivo microvascular function.
Sites (1)
- Medical College of Wisconsin, Milwaukee, Wisconsin, United States